Evidence map›Paper›PMID 30944653›Full record

ArticleOncology letters2019

Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer.

Wanhua Wu, Shoumin Bai, Dingjun Zhu, Kaiwen Li, Wen Dong, Wang He, Shengmeng Peng, Yiming Lai, Qiong Wang, Zhenghui Guo and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. CircZNF236 facilitates malignant progression in oral squamous cell carcinoma by sequestering miR-145-5p.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Wanhua WuDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Shoumin BaiDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Dingjun ZhuDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Kaiwen LiDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Wen DongDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Wang HeDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Shengmeng PengDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Yiming LaiDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Qiong WangDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Zhenghui GuoDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Leyuan LiuInstitute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX 77030, USA.
Hai HuangDepartment of Urology, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Sun Yat-sen University · CNSun Yat-sen Memorial Hospital · CNTexas A&M Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant brain tumor domain containing protein 1 (MBTD1) is a member of the polycomb group protein family that is associated with tumorigenesis. The present study investigated the role of MBTD1 within defined clinicopathological parameters and the prognosis of patients with prostate cancer (PCa). A human tissue microarray containing samples from 71 patients with PCa and seven healthy donors was employed for immunohistochemistry (IHC). The clinicopathological characteristics and prognostic value of MBTD1 were investigated using a dataset of 499 patients from The Cancer Genome Atlas (TCGA). IHC illustrated that the levels of MBTD1 protein were enhanced and markedly associated with aggressive clinical stage and advanced tumor invasion, distant metastasis and lymph node metastasis in patients with PCa. In the TCGA data set, the level of MBTD1 was found to positively correlate with the prostate-specific antigen level, Gleason score and distant metastasis. The multivariate analysis of Cox regression revealed that the levels of MBTD1 may act as an independent prognostic factor for low non-biochemical, recurrence-free survival. In conclusion, MBTD1 was overexpressed in PCa tissues and is associated with aggressive clinicopathological characteristics. It may therefore act as a novel prognostic factor and diagnostic marker in PCa.

Indexed as

MBTD1metastasisprognosisprostate carcinomasurvival

Identifiers

PMID30944653
PMCPMC6444442
OpenAlexW2918749138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.